Furthermore, since SMYD3 has been reported to modulate an ATM-related pathway in GC cells, it may also be involved in DDR processes in this cancer type, as has already been observed in other tumors, thus gaining ground as an interesting therapeutic target [112,113,114]. The gene discussed is SMYD3; the disease is cancer.